Kissei Pharmaceutical
Kissei Pharmaceutical Co Ltd is a Japanese multinational biopharmaceutical research and manufacturing enterprise specializing in the discovery, clinical development, production, and global commercialization of prescription pharmaceutical medicines and therapeutic drugs, prominently featuring specialized treatments for metabolic diseases, urological disorders, nephrology, and rare conditions distributed across Japan and international medical markets. Operating advanced pharmaceutical R&D laboratories and manufacturing complexes in Japan, the company drives medical innovation. Its core business operations encompass pharmaceutical drug discovery, clinical-stage drug development, biological manufacturing, and international commercial distribution. Revenue is derived primarily from commercial product sales of prescription pharmaceuticals and cooperative licensing agreements with global pharmaceutical partners. Kissei Pharmaceutical holds a leading market position in metabolic and urological therapeutics in Japan. The company is headquartered in Matsumoto, Nagano Prefecture, Japan, and its shares trade on the Tokyo Stock Exchange (TSE Prime Market).
4 of the funds FundTelligence covers report a position in Kissei Pharmaceutical.
- Legal name
- Kissei Pharmaceutical Co Ltd
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 4
Funds holding Kissei Pharmaceutical
- Mercer Global Small Cap Equity Fund — Mercer · 0.14 % (full portfolio disclosed, December 2025)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)